查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600441

制酸劑市場：依藥物類別、劑型、適應症、通路分類 - 全球預測 2025-2030

Antacids Market by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents), Formulation (Liquid, Powder, Tablet), Indication, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年制酸劑市值為68.5億美元，預計到2024年將達到72.4億美元，複合年成長率為5.81%，到2030年將達到101.8億美元。

制酸劑市場包括各種非處方藥和處方藥，旨在中和胃酸並緩解與胃酸倒流、消化不良和胃灼熱相關的症狀。由於不健康的飲食、壓力和久坐的生活方式等生活方式因素引起胃腸道疾病的廣泛流行，因此需要制酸劑。制酸劑的應用主要在醫療保健和製藥業，針對需要立即緩解消化器官系統不適的消費者。制酸劑被多種人群使用，包括老年人、孕婦和患有慢性胃腸道問題的人。市場成長的推動因素包括胃腸道健康意識的提高、自我治療趨勢的增加以及咀嚼片和調味片的日益普及，這些片劑吸引了更廣泛的人群。

主要市場統計
基準年[2023] 68.5億美元
預測年份 [2024] 72.4億美元
預測年份 [2030] 101.8億美元
複合年成長率（%） 5.81%

主要影響因素是全球胃腸道疾病增加導致消化器官系統健康市場快速成長。潛在的成長機會存在於中產階級人口不斷成長和醫療保健意識增強的新興市場。公司應投資創新產品配方，以滿足注重健康的消費者的需求，例如砂糖、純素和有機產品。然而，監管障礙、長期使用的潛在副作用以及質子幫浦阻斷劑和 H2 受體拮抗劑等替代療法的競爭等挑戰可能會阻礙市場成長。此外，錯誤訊息和缺乏正確使用意識可能會導致消費者困惑。

為了克服這些限制，需要進行研究和開發來延長鬆弛時間、最大限度地減少副作用並提高患者的依從性。增強的遞送機制，例如速效液體製劑和可溶性條帶，也可以提高競爭力。關於抗酸化合物和腸道微生物群相互作用的高級研究為個人化胃腸道護理提供了尚未開發的潛力。制酸劑市場是動態的、由消費者主導的，需要不斷創新和策略行銷來應對不斷變化的消費者需求和偏好，同時克服監管和競爭挑戰。

市場動態：揭示快速發展的制酸劑市場的關鍵市場洞察

供需的動態交互作用正在改變制酸劑市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 胃食道逆流病人口增加
    • 全球政府對國內藥品製造的措施與投資
  • 市場限制因素
    • 針對酸相關問題的家庭療法和其他替代方法的可用性
  • 市場機會
    • 開發效果更立竿見影、效果更持久的制酸劑
    • 在線藥房可以輕鬆獲得制酸劑，並且成藥的監管靈活性
  • 市場挑戰
    • 與制酸劑相關的藥品召回和污染問題

波特的五力：駕馭制酸劑市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解制酸劑市場的外部影響

外部宏觀環境因素在塑造制酸劑市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解制酸劑市場的競爭狀況

制酸劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣制酸劑市場供應商績效評估

FPNV定位矩陣是評估制酸劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 患有胃食道逆流的人數正在增加
      • 全球政府對國內藥品製造的措施與投資
    • 抑制因素
      • 針對酸度相關問題的家庭療法和其他替代療法的可用性
    • 機會
      • 開發具有更直接和持久效果的制酸劑
      • 線上藥局可以輕鬆可得性制酸劑，並且成藥的監管靈活性
    • 任務
      • 與制酸劑相關的藥品召回和污染問題
  • 市場區隔分析
    • 藥物類別：酸中和劑越來越受歡迎以提高治療效果
    • 適應症：在胃食道逆流症的治療中越來越需要制酸劑，以減少胃酸對食道內壁的損害。
    • 配方：人們越來越喜歡液體制酸劑，因為它們在溶解狀態下可以更快地緩解症狀。
    • 通路：零售藥局制酸劑的供應量增加，無需處方箋即可輕鬆取得制酸劑
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的制酸劑市場

  • 酸中和劑
    • 氫氧化鋁
    • 碳酸鈣
    • 氫氧化鎂
    • 碳酸氫鈉
  • H2拮抗劑
  • 促銷代理
  • 質子幫浦抑制劑

第7章 處方制酸劑市場

  • 液體
  • 粉末
  • 錠劑

第8章按適應症分類的制酸劑市場

  • 胃食道逆流症
  • 消化不良/消化不良
  • 消化性潰瘍

第9章制酸劑市場：按通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲制酸劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太制酸劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲/中東/非洲制酸劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • TUMS 與 DraftKings 和 Desus Nice 合作推出TUMS Prop Bites，讓大型遊戲迷第一次可以盡情享受美食。
    • Dexel Pharma 收購八個 OTC 品牌以強化消費者保健產品組合
    • Camber Pharmaceuticals 推出非專利Wellbutrin SR
    • 利潔時在泰米爾納德邦推出 Gaviscon Double Action，幫助患有胃酸過多和胃灼熱的人們
    • Wonderberry 擴展到 1,800 多家 Target 商店，以便更輕鬆地接觸更廣泛的客戶群
    • 剪切機-Smith 推出法莫替丁口服懸浮液
    • ZydusEsomeprazole唑鎂產品獲得美國FDA 最終核准
    • Wonder Berry制酸劑為目標族群提供獨特口味
    • Mark Sands Pharma 法莫替丁錠獲得美國FDA核准
    • ENO 推出兩種新口味擴大產品組合：Jaljeera 和 Nimbu Masala

公司名單

  • Abbott Laboratories
  • Aero Healthcare AU Pty Ltd
  • Alcon Industries
  • Alkem Laboratories Ltd.
  • Allegiant Health
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Camber Pharmaceuticals, Inc.
  • Cipla Limited
  • Daiichi Sankyo Company Limited
  • Dexcel Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline PLC
  • Haleon PLC
  • Imerys SA
  • JB Chemicals & Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Magmit Pharmaceutical Co., Ltd.
  • Mankind Pharma Ltd.
  • Marksans Pharma
  • Nestle SA
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Raritan Pharmaceuticals, Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Swiss Chem Healthcare by Swastik Lifesciences
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals
  • Wonderbelly
  • Zoic Pharmaceuticals Pvt. Ltd.
Product Code: MRR-4358BACA7E3E

The Antacids Market was valued at USD 6.85 billion in 2023, expected to reach USD 7.24 billion in 2024, and is projected to grow at a CAGR of 5.81%, to USD 10.18 billion by 2030.

The antacids market encompasses a wide range of over-the-counter and prescription medications intended to neutralize stomach acidity and alleviate symptoms associated with acid reflux, indigestion, and heartburn. The necessity of antacids stems from the widespread prevalence of gastrointestinal diseases caused by lifestyle factors such as unhealthy diets, stress, and sedentary habits. Their application is primarily within the healthcare and pharmaceutical industries, targeting consumers in need of immediate relief from digestive discomfort. Antacids are used by a diverse demographic, including older adults, pregnant women, and individuals with chronic gastrointestinal issues. The market's growth is fueled by rising awareness of gastrointestinal health, increased self-medication trends, and the rising popularity of chewable tablets and flavored versions that appeal to a broader audience.

KEY MARKET STATISTICS
Base Year [2023] USD 6.85 billion
Estimated Year [2024] USD 7.24 billion
Forecast Year [2030] USD 10.18 billion
CAGR (%) 5.81%

A key influencing factor is the burgeoning digestive health market, driven by the increase in gastrointestinal diseases globally. Potential growth opportunities reside in emerging markets with a rising middle-class population and increasing healthcare awareness. Companies should invest in innovative product formulations like sugar-free, vegan-friendly, and organic antacids that cater to health-conscious consumers. However, challenges such as regulatory hurdles, the potential side effects of long-term use, and competition from alternative treatments like proton pump inhibitors and H2-receptor antagonists may hinder market growth. Furthermore, misinformation and a lack of awareness regarding appropriate usage can lead consumers astray.

To overcome these limitations, research can be directed towards developing antacids with extended relief duration, minimal side effects, and improved patient compliance. Enhanced delivery mechanisms like fast-acting liquid formulations or dissolvable strips could also provide a competitive edge. Advanced studies on gut microbiota interactions with antacid compounds offer untapped potential for personalized digestive care. The antacids market is dynamic and consumer-driven, requiring continuous innovation and strategic marketing to cater to varying consumer needs and preferences while navigating the challenges posed by regulation and competition.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antacids Market

The Antacids Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing population suffering from gastroesophageal reflux disease
    • Government initiatives and investments for domestic drug manufacturing worldwide
  • Market Restraints
    • Availability of home remedies and other alternatives for acidity-related issues
  • Market Opportunities
    • Development of more instantly effective and long-lasting antacids
    • Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
  • Market Challenges
    • Drug recall and contamination issues associated with the antacids

Porter's Five Forces: A Strategic Tool for Navigating the Antacids Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antacids Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antacids Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antacids Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antacids Market

A detailed market share analysis in the Antacids Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antacids Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antacids Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antacids Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aero Healthcare AU Pty Ltd, Alcon Industries, Alkem Laboratories Ltd., Allegiant Health, AstraZeneca plc, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals, Inc., Cipla Limited, Daiichi Sankyo Company Limited, Dexcel Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Haleon PLC, Imerys S.A., J. B. Chemicals & Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Magmit Pharmaceutical Co., Ltd., Mankind Pharma Ltd., Marksans Pharma, Nestle S.A., Novartis AG, Perrigo Company plc, Pfizer Inc., Raritan Pharmaceuticals, Inc., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Swiss Chem Healthcare by Swastik Lifesciences, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals, Wonderbelly, and Zoic Pharmaceuticals Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Antacids Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Acid Neutralizers, H2 Antagonist, Promotility Agents, and Proton Pump Inhibitor. The Acid Neutralizers is further studied across Aluminum Hydroxide, Calcium Carbonate, Magnesium Hydroxide, and Sodium Bicarbonate.
  • Based on Formulation, market is studied across Liquid, Powder, and Tablet.
  • Based on Indication, market is studied across Gastroesophageal Reflux Disease, Indigestion/Dyspepsia, and Peptic Ulcer Disease.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing population suffering from gastroesophageal reflux disease
      • 5.1.1.2. Government initiatives and investments for domestic drug manufacturing worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of home remedies and other alternatives for acidity-related issues
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of more instantly effective and long-lasting antacids
      • 5.1.3.2. Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Drug recall and contamination issues associated with the antacids
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing preference for acid neutralizers for improved therapeutic action
    • 5.2.2. Indication: Expanding need for antacids for the management of gastroesophageal reflux disease for reducing the acid's ability to damage the esophageal lining.
    • 5.2.3. Formulation: Rising preference for liquid antacid due to their already dissolved state, facilitating quicker relief from symptoms
    • 5.2.4. Distribution Channel: Growing availability of antacids across retail pharmacies that provide instant access to antacids without the need for a prescription
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antacids Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Acid Neutralizers
    • 6.2.1. Aluminum Hydroxide
    • 6.2.2. Calcium Carbonate
    • 6.2.3. Magnesium Hydroxide
    • 6.2.4. Sodium Bicarbonate
  • 6.3. H2 Antagonist
  • 6.4. Promotility Agents
  • 6.5. Proton Pump Inhibitor

7. Antacids Market, by Formulation

  • 7.1. Introduction
  • 7.2. Liquid
  • 7.3. Powder
  • 7.4. Tablet

8. Antacids Market, by Indication

  • 8.1. Introduction
  • 8.2. Gastroesophageal Reflux Disease
  • 8.3. Indigestion/Dyspepsia
  • 8.4. Peptic Ulcer Disease

9. Antacids Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Antacids Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antacids Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antacids Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
    • 13.3.2. Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio
    • 13.3.3. Camber Pharmaceuticals Launches Generic Wellbutrin SR
    • 13.3.4. Reckitt Launches Gaviscon Double Action in Tamil Nadu, Helping People with Acidity and Heartburn
    • 13.3.5. Wonderbelly Expands To Over 1,800 Target Stores to be Easily Accessible to a Broader Audience
    • 13.3.6. Upsher-Smith Launches Famotidine For Oral Suspension
    • 13.3.7. Zydus Secures Final Approval from the USFDA for its Esomeprazole Magnesium Product
    • 13.3.8. Wonderbelly Antacid Brings Exclusive Flavor to Target With Launch
    • 13.3.9. Marksans Pharma Gets USFDA Nod for Famotidine Tablets
    • 13.3.10. ENO Expands its Portfolio with Two New Flavors, Jaljeera and Nimbu Masala

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Aero Healthcare AU Pty Ltd
  • 3. Alcon Industries
  • 4. Alkem Laboratories Ltd.
  • 5. Allegiant Health
  • 6. AstraZeneca plc
  • 7. Bayer AG
  • 8. Biocon Limited
  • 9. Boehringer Ingelheim International GmbH
  • 10. Cadila Pharmaceuticals Limited
  • 11. Camber Pharmaceuticals, Inc.
  • 12. Cipla Limited
  • 13. Daiichi Sankyo Company Limited
  • 14. Dexcel Ltd.
  • 15. Dr. Reddy's Laboratories Ltd.
  • 16. GlaxoSmithKline PLC
  • 17. Haleon PLC
  • 18. Imerys S.A.
  • 19. J. B. Chemicals & Pharmaceuticals Limited
  • 20. Johnson & Johnson Services, Inc.
  • 21. Magmit Pharmaceutical Co., Ltd.
  • 22. Mankind Pharma Ltd.
  • 23. Marksans Pharma
  • 24. Nestle S.A.
  • 25. Novartis AG
  • 26. Perrigo Company plc
  • 27. Pfizer Inc.
  • 28. Raritan Pharmaceuticals, Inc.
  • 29. Reckitt Benckiser Group PLC
  • 30. Sanofi S.A.
  • 31. Sun Pharmaceutical Industries Ltd.
  • 32. Swiss Chem Healthcare by Swastik Lifesciences
  • 33. Takeda Pharmaceutical Company Limited
  • 34. Teva Pharmaceutical Industries Ltd.
  • 35. The Procter & Gamble Company
  • 36. Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals
  • 37. Wonderbelly
  • 38. Zoic Pharmaceuticals Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTACIDS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTACIDS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTACIDS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTACIDS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTACIDS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTACIDS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTACIDS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTACIDS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTACIDS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTACIDS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTACIDS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTACIDS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTACIDS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTACIDS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTACIDS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTACIDS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTACIDS MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTACIDS MARKET SIZE, BY PROMOTILITY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTACIDS MARKET SIZE, BY PROTON PUMP INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTACIDS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTACIDS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTACIDS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTACIDS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTACIDS MARKET SIZE, BY INDIGESTION/DYSPEPSIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTACIDS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTACIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTACIDS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTACIDS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTACIDS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. ANTACIDS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. ANTACIDS MARKET, FPNV POSITIONING MATRIX, 2023